Published in Proc Natl Acad Sci U S A on October 01, 1989
A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family. EMBO J (1990) 9.17
Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Mol Cell Biol (1990) 6.57
Organization of immunological memory by bone marrow stroma. Nat Rev Immunol (2010) 3.57
Lymphoproliferative disorder and imbalanced T-helper response in C/EBP beta-deficient mice. EMBO J (1995) 3.48
In vivo regulation of Bcl6 and T follicular helper cell development. J Immunol (2010) 2.63
Constitutive and interleukin-1 (IL-1)-inducible factors interact with the IL-1-responsive element in the IL-6 gene. Mol Cell Biol (1990) 2.41
The induction of antibody production by IL-6 is indirectly mediated by IL-21 produced by CD4+ T cells. J Exp Med (2009) 2.38
Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. J Clin Invest (1990) 2.37
Continuous anti-interleukin 10 antibody administration depletes mice of Ly-1 B cells but not conventional B cells. J Exp Med (1992) 2.15
IL-6 as a keystone cytokine in health and disease. Nat Immunol (2015) 2.14
Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc Natl Acad Sci U S A (1995) 2.05
Induction of lupus-associated autoantibodies in BALB/c mice by intraperitoneal injection of pristane. J Exp Med (1994) 2.02
Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice. Proc Natl Acad Sci U S A (1992) 2.01
Human IL6 enhances leptin action in mice. Diabetologia (2009) 1.98
Glomerulosclerosis induced by in vivo transfection of transforming growth factor-beta or platelet-derived growth factor gene into the rat kidney. J Clin Invest (1993) 1.97
Airway epithelial cell expression of interleukin-6 in transgenic mice. Uncoupling of airway inflammation and bronchial hyperreactivity. J Clin Invest (1994) 1.96
Interleukin 6 influences germinal center development and antibody production via a contribution of C3 complement component. J Exp Med (1998) 1.78
Survival and proliferation factors of normal and malignant plasma cells. Int J Hematol (2003) 1.76
Transplantable myeloproliferative disease induced in mice by an interleukin 6 retrovirus. J Exp Med (1992) 1.74
TANK is a negative regulator of Toll-like receptor signaling and is critical for the prevention of autoimmune nephritis. Nat Immunol (2009) 1.72
Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice. J Clin Invest (1996) 1.67
Postnatally induced inactivation of gp130 in mice results in neurological, cardiac, hematopoietic, immunological, hepatic, and pulmonary defects. J Exp Med (1998) 1.65
Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors. J Exp Med (1995) 1.60
Transplantation of T cell-mediated, lymphoreticular disease from the scurfy (sf) mouse. Am J Pathol (1994) 1.59
Targeted expression of IL-11 in the murine airway causes lymphocytic inflammation, bronchial remodeling, and airways obstruction. J Clin Invest (1996) 1.58
Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. J Clin Invest (1994) 1.56
Anti-nuclear antibody production and immune-complex glomerulonephritis in BALB/c mice treated with pristane. Proc Natl Acad Sci U S A (1995) 1.56
Anti-interleukin 6 receptor antibody treatment in rheumatic disease. Ann Rheum Dis (2000) 1.56
Defective gp130-mediated signal transducer and activator of transcription (STAT) signaling results in degenerative joint disease, gastrointestinal ulceration, and failure of uterine implantation. J Exp Med (2001) 1.55
IL-6 transgenic mouse model for extraosseous plasmacytoma. Proc Natl Acad Sci U S A (2002) 1.55
A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells. Oncogene (2003) 1.54
Positive regulators of osteoclastogenesis and bone resorption in rheumatoid arthritis. Arthritis Res Ther (2011) 1.51
gp130 at the nexus of inflammation, autoimmunity, and cancer. J Leukoc Biol (2010) 1.48
Cytokines, leptin, and stress-induced thymic atrophy. J Leukoc Biol (2008) 1.47
Expression of HLA class II molecules in humanized NOD.Rag1KO.IL2RgcKO mice is critical for development and function of human T and B cells. PLoS One (2011) 1.41
Interleukin-1 beta and tumor necrosis factor-alpha induce gene expression and production of leukocyte chemotactic factors, colony-stimulating factors, and interleukin-6 in human mesangial cells. Am J Pathol (1991) 1.41
Hepatitis C virus induces toll-like receptor 4 expression, leading to enhanced production of beta interferon and interleukin-6. J Virol (2006) 1.38
Interleukin 6: insights to its function in skin by overexpression in transgenic mice. Proc Natl Acad Sci U S A (1992) 1.37
Interleukin-6 exacerbates glomerulonephritis in (NZB x NZW)F1 mice. Am J Pathol (1994) 1.32
Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases. Int J Biol Sci (2012) 1.27
Mouse plasmacytoma growth in vivo: enhancement by interleukin 6 (IL-6) and inhibition by antibodies directed against IL-6 or its receptor. J Exp Med (1990) 1.24
Transgenic mouse model of AA amyloidosis. Am J Pathol (1999) 1.21
Epidermal loss of JunB leads to a SLE phenotype due to hyper IL-6 signaling. Proc Natl Acad Sci U S A (2009) 1.20
Hepatocellular hyperplasia, plasmacytoma formation, and extramedullary hematopoiesis in interleukin (IL)-6/soluble IL-6 receptor double-transgenic mice. Am J Pathol (1998) 1.19
Transforming growth factor-beta and suppression of humoral immune responses in HIV infection. J Clin Invest (1991) 1.18
Expression of an exogenous interleukin 6 gene in human Epstein Barr virus B cells confers growth advantage and in vivo tumorigenicity. J Exp Med (1990) 1.14
HHV-8-encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in mice. Blood (2012) 1.14
IL-6 blocks a discrete early step in lymphopoiesis. Blood (2005) 1.14
Extramedullary expansion of hematopoietic progenitor cells in interleukin (IL)-6-sIL-6R double transgenic mice. J Exp Med (1997) 1.13
Microarray-based understanding of normal and malignant plasma cells. Immunol Rev (2006) 1.12
Selective induction of immune responses by cytokines coexpressed in recombinant fowlpox virus. J Virol (1994) 1.12
Inhibition of IL-1, IL-6, and TNF-alpha in immune-mediated inflammatory diseases. Springer Semin Immunopathol (2006) 1.11
Generation of interleukin-6 receptor antagonists by molecular-modeling guided mutagenesis of residues important for gp130 activation. EMBO J (1994) 1.10
Mitogenic effect of platelet-derived growth factor in human glomerular mesangial cells: modulation and/or suppression by inflammatory cytokines. Clin Exp Immunol (1991) 1.07
Src homology 2-containing 5-inositol phosphatase (SHIP) suppresses an early stage of lymphoid cell development through elevated interleukin-6 production by myeloid cells in bone marrow. J Exp Med (2004) 1.06
A role for interleukin-6 in host defense against murine Chlamydia trachomatis infection. Infect Immun (1998) 1.05
(18)F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib. Blood Cancer J (2013) 1.03
Cytokines in systemic lupus erythematosus. Curr Mol Med (2009) 1.03
B-cell activation following murine cytomegalovirus infection: implications for autoimmunity. Immunology (1993) 1.02
Bone marrow neutrophilia and suppressed bone turnover in human interleukin-6 transgenic mice. A cellular relationship among hematopoietic cells, osteoblasts, and osteoclasts mediated by stromal cells in bone marrow. Am J Pathol (1995) 1.01
Expression of LIF in transgenic mice results in altered thymic epithelium and apparent interconversion of thymic and lymph node morphologies. EMBO J (1994) 1.01
Interleukin 6 and rheumatoid arthritis. Biomed Res Int (2014) 1.00
Restricting activation-induced cytidine deaminase tumorigenic activity in B lymphocytes. Immunology (2009) 0.98
Alternate mechanisms of initial pattern recognition drive differential immune responses to related poxviruses. Cell Host Microbe (2010) 0.97
Interleukin-6 is necessary, but not sufficient, for induction of the humanC-reactive protein gene in vivo. Biochem J (1997) 0.97
Interleukin-6 antisense oligonucleotides inhibit the growth of human myeloma cell lines. J Clin Invest (1991) 0.95
IL-6 increases B-cell IgG production in a feed-forward proinflammatory mechanism to skew hematopoiesis and elevate myeloid production. Blood (2010) 0.95
Functional murine interleukin 6 receptor with the intracisternal A particle gene product at its cytoplasmic domain. Its possible role in plasmacytomagenesis. J Exp Med (1990) 0.95
Disparate T cell requirements of two subsets of lupus-specific autoantibodies in pristane-treated mice. Clin Exp Immunol (1999) 0.95
Neurotrophins regulate bone marrow stromal cell IL-6 expression through the MAPK pathway. PLoS One (2010) 0.95
Peripheral blood CD4(+)CD25(+)CD127(low) regulatory T cells are significantly increased by tocilizumab treatment in patients with rheumatoid arthritis: increase in regulatory T cells correlates with clinical response. Arthritis Res Ther (2015) 0.94
Rational design of a receptor super-antagonist of human interleukin-6. EMBO J (1994) 0.94
Involvement of gp130-mediated signaling in pressure overload-induced activation of the JAK/STAT pathway in rodent heart. Heart Vessels (1998) 0.94
Dichloroacetate alleviates development of collagen II-induced arthritis in female DBA/1 mice. Arthritis Res Ther (2009) 0.93
Lymphoid hyperplasia in transgenic mice over-expressing a secreted form of the human interleukin-1beta gene product. Immunology (1999) 0.93
Interleukin-6 cDNA transfected Lewis lung carcinoma cells show unaltered net tumour growth rate but cause weight loss and shortened survival in syngeneic mice. Br J Cancer (1993) 0.92
Enhancement of in vitro and in vivo antigen-specific antibody responses by interleukin 11. J Exp Med (1992) 0.92
Transcriptional modulation of heat-shock protein gene expression. Biochem Res Int (2010) 0.91
Natural IgM is produced by CD5- plasma cells that occupy a distinct survival niche in bone marrow. J Immunol (2014) 0.90
Viral interleukin-6: role in Kaposi's sarcoma-associated herpesvirus: associated malignancies. J Interferon Cytokine Res (2011) 0.89
Cytokines and their receptors in cardiovascular diseases--role of gp130 signalling pathway in cardiac myocyte growth and maintenance. Int J Exp Pathol (2000) 0.89
In vivo effects of anticytokine antibodies on isotype restriction in Mesocestoides corti-infected BALB/c mice. Infect Immun (1991) 0.89
Separate checkpoints regulate splenic plasma cell accumulation and IgG autoantibody production in Lyn-deficient mice. Eur J Immunol (2010) 0.87
Imbalances in serum proinflammatory cytokines and their soluble receptors: a putative role in the progression of idiopathic IgA nephropathy (IgAN) and Henoch-Schönlein purpura nephritis, and a potential target of immunoglobulin therapy? Clin Exp Immunol (1998) 0.87
Urinary IL-6: a marker for mesangial proliferative glomerulonephritis? Clin Exp Immunol (1991) 0.86
Consistent loss of functional transforming growth factor beta receptor expression in murine plasmacytomas. Proc Natl Acad Sci U S A (1998) 0.86
Inflammatory mediators increase surface expression of integrin ligands, adhesion to lymphocytes, and secretion of interleukin 6 in mouse Sertoli cells. Proc Natl Acad Sci U S A (1995) 0.86
Gene expression profiling reveals different pathways related to Abl and other genes that cooperate with c-Myc in a model of plasma cell neoplasia. BMC Genomics (2007) 0.86
Progenitor cell hyperplasia with rare development of myeloid leukemia in interleukin 11 bone marrow chimeras. J Exp Med (1993) 0.85
Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies. Leuk Lymphoma (2014) 0.84
Immunosuppressant FK506 induces interleukin-6 production through the activation of transcription factor nuclear factor (NF)-kappa(B). Implications for FK506 nephropathy. J Clin Invest (1996) 0.83
A prospective study of renal disease in patients with early rheumatoid arthritis. Ann Rheum Dis (2001) 0.83
A granulocyte inhibitory protein overexpressed in chronic renal disease regulates expression of interleukin 6 and interleukin 8. Proc Natl Acad Sci U S A (1994) 0.82
IL-6 Trans-Signaling Drives Murine Crescentic GN. J Am Soc Nephrol (2015) 0.82
Interleukin-6 deficiency corrects nephritis, lymphocyte abnormalities, and secondary Sjögren's syndrome features in lupus-prone Sle1.Yaa mice. Arthritis Rheumatol (2014) 0.82
Islet inflammation and hyperplasia induced by the pancreatic islet-specific overexpression of interleukin-6 in transgenic mice. Am J Pathol (1994) 0.82
IL-6 Plays a Crucial Role in HBV Infection. J Clin Transl Hepatol (2015) 0.82
Neuroprotective effects of cardiotrophin-like cytokine on retinal ganglion cells. Graefes Arch Clin Exp Ophthalmol (2005) 0.81
Decreased leukocyte accumulation and delayed Bordetella pertussis clearance in IL-6-/- mice. J Immunol (2011) 0.81
Transgenic mice in the study of cytokine function. Int J Exp Pathol (1993) 0.81
Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature (1986) 9.63
Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci U S A (1987) 9.26
Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer (1972) 7.70
Purification and NH2-terminal amino acid sequence of a T-cell-derived lymphokine with growth factor activity for B-cell hybridomas. Proc Natl Acad Sci U S A (1986) 5.60
Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature (1988) 5.60
Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol (1988) 4.20
Molecular regulation of B lymphocyte response. Annu Rev Immunol (1988) 3.68
Structure and expression of human B cell stimulatory factor-2 (BSF-2/IL-6) gene. EMBO J (1987) 3.64
A macrophage-derived factor required by plasmacytomas for survival and proliferation in vitro. Science (1986) 3.28
Rapid viral induction of plasmacytomas in pristane-primed BALB-c mice. Science (1973) 2.94
Activation of a translocated human c-myc gene by an enhancer in the immunoglobulin heavy-chain locus. Nature (1984) 2.93
Nonrandom chromosome changes involving the Ig gene-carrying chromosomes 12 and 6 in pristane-induced mouse plasmacytomas. Cell (1979) 2.92
Human B-cell differentiation factor defined by an anti-peptide antibody and its possible role in autoantibody production. Proc Natl Acad Sci U S A (1987) 2.76
Induction of plasma-cell neoplasms in strain BALB/c mice with mineral oil and mineral oil adjuvants. Nature (1962) 2.74
Establishment of an interleukin 6 (IL 6)/B cell stimulatory factor 2-dependent cell line and preparation of anti-IL 6 monoclonal antibodies. Eur J Immunol (1988) 2.41
Receptors for B cell stimulatory factor 2. Quantitation, specificity, distribution, and regulation of their expression. J Exp Med (1987) 2.34
cDNA cloning of murine interleukin-HP1: homology with human interleukin 6. Eur J Immunol (1988) 2.26
Increased expression of myc-related oncogene mRNA characterizes most BALB/c plasmacytomas induced by pristane or Abelson murine leukemia virus. Proc Natl Acad Sci U S A (1983) 2.16
Recombinant human B cell stimulatory factor 2 (BSF-2/IFN-beta 2) regulates beta-fibrinogen and albumin mRNA levels in Fao-9 cells. FEBS Lett (1987) 2.04
Human interleukin 6 is a direct promoter of maturation of megakaryocytes in vitro. Proc Natl Acad Sci U S A (1989) 1.69
Paraproteinemia and reticulum cell sarcoma in an inbred mouse strain. Science (1966) 1.65
Purification and NH2-terminal sequence of a plasmacytoma growth factor derived from the murine macrophage cell line P388D1. J Immunol (1987) 1.55
Pathologic conditions associated with plasma cell dyscrasias: a study of 806 cases. Ann N Y Acad Sci (1971) 1.48
Introduction of human gamma 1 immunoglobulin genes into fertilized mouse eggs. J Biochem (1984) 1.35
Immunocytology of cultured IgM-forming cells of mouse. I. Requirement of phagocytic cell factor for the growth of IgM-forming tumor cells in tissue culture. J Immunol (1972) 1.30
Differentiation of B cell progenitors in vitro: generation of surface IgM+ B cells, including Ly-1 B cells, from Thy-1- asialoGM1+ cells in newborn liver. Eur J Immunol (1987) 1.26
Avian v-myc replaces chromosomal translocation in murine plasmacytomagenesis. Science (1987) 1.20
Functional expression of a microinjected Ed alpha gene in C57BL/6 transgenic mice. Nature (1985) 1.18
Rapid induction of IgM-secreting murine plasmacytomas by pristane and an immunoglobulin heavy-chain promoter/enhancer-driven c-myc/v-Ha-ras retrovirus. Proc Natl Acad Sci U S A (1988) 1.16
Rheumatoid arthritis terminating in plasmocytoma. Acta Med Scand (1970) 1.06
Atrial myxoma with multiple myeloma. Arch Intern Med (1979) 0.87
Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene (1991) 38.64
The transcriptional landscape of the mammalian genome. Science (2005) 37.63
A Toll-like receptor recognizes bacterial DNA. Nature (2000) 26.34
Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet (2000) 21.52
Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell (1997) 18.91
Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity (1998) 18.12
Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity (1999) 17.40
Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol (1999) 16.86
The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature (2001) 14.24
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med (1996) 13.49
Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity (1999) 11.64
Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature (1996) 10.67
Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature (1986) 9.63
TLR signaling. Cell Death Differ (2006) 9.24
A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family. EMBO J (1990) 9.17
Engineered GFP as a vital reporter in plants. Curr Biol (1996) 9.03
Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature (1994) 8.85
Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity (1999) 7.90
Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proc Natl Acad Sci U S A (1998) 7.69
Toll-like receptors control activation of adaptive immune responses. Nat Immunol (2001) 7.54
The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature (1998) 7.38
Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci U S A (1997) 7.08
Cutting edge: TLR2-deficient and MyD88-deficient mice are highly susceptible to Staphylococcus aureus infection. J Immunol (2000) 6.61
Essential role of Stat6 in IL-4 signalling. Nature (1996) 6.56
Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell (1994) 6.45
Establishment of a pancreatic beta cell line that retains glucose-inducible insulin secretion: special reference to expression of glucose transporter isoforms. Endocrinology (1990) 6.34
The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. Immunity (1994) 6.18
Structure and function of a new STAT-induced STAT inhibitor. Nature (1997) 6.02
EUROCARE-3: survival of cancer patients diagnosed 1990-94--results and commentary. Ann Oncol (2003) 5.78
Identification of Xenopus SMC protein complexes required for sister chromatid cohesion. Genes Dev (1998) 5.78
Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell (1989) 5.72
Epstein-Barr virus nuclear antigen 2 specifically induces expression of the B-cell activation antigen CD23. Proc Natl Acad Sci U S A (1987) 5.68
Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol (2001) 5.62
Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature (1988) 5.60
Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol (1997) 5.38
Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int Immunol (2001) 5.36
Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. J Immunol (2001) 5.27
Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum (2006) 5.20
Biological and clinical aspects of interleukin 6. Immunol Today (1990) 5.17
Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF). FASEB J (1990) 5.16
Cytokine signal transduction. Cell (1994) 5.14
Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell (1990) 5.06
Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci U S A (2001) 5.02
Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. Science (1988) 4.93
Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice. J Immunol (1998) 4.74
Defective NK cell activity and Th1 response in IL-18-deficient mice. Immunity (1998) 4.70
Differential regulation of mammalian period genes and circadian rhythmicity by cryptochromes 1 and 2. Proc Natl Acad Sci U S A (1999) 4.62
Interleukin-6 family of cytokines and gp130. Blood (1995) 4.52
Defective adipocyte differentiation in mice lacking the C/EBPbeta and/or C/EBPdelta gene. EMBO J (1997) 4.51
Induction of direct antimicrobial activity through mammalian toll-like receptors. Science (2001) 4.46
Targeted disruption of the NF-IL6 gene discloses its essential role in bacteria killing and tumor cytotoxicity by macrophages. Cell (1995) 4.34
Endovascular stent-graft placement for the treatment of acute aortic dissection. N Engl J Med (1999) 4.33
The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med (1988) 4.31
Site-specific recombination of a transgene in fertilized eggs by transient expression of Cre recombinase. Proc Natl Acad Sci U S A (1995) 4.28
Molecular cloning and structure of a pre-B-cell growth-stimulating factor. Proc Natl Acad Sci U S A (1994) 4.25
Transcription factors NF-IL6 and NF-kappa B synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8. Proc Natl Acad Sci U S A (1993) 4.23
Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol (1988) 4.20
Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood (1989) 4.17
Cutting edge: endotoxin tolerance in mouse peritoneal macrophages correlates with down-regulation of surface toll-like receptor 4 expression. J Immunol (2000) 4.10
Interleukin-6 in biology and medicine. Adv Immunol (1993) 4.06
A novel reporter mouse strain that expresses enhanced green fluorescent protein upon Cre-mediated recombination. FEBS Lett (2000) 4.03
Evolution from fish to mammals by gene duplication. Hereditas (1968) 3.95
ATP-dependent positive supercoiling of DNA by 13S condensin: a biochemical implication for chromosome condensation. Cell (1997) 3.95
Gene transfer into muscle by electroporation in vivo. Nat Biotechnol (1998) 3.89
Phosphorylation and activation of 13S condensin by Cdc2 in vitro. Science (1998) 3.89
Infection with HIV is associated with elevated IL-6 levels and production. J Immunol (1990) 3.89
Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res (2000) 3.86
Limb and skin abnormalities in mice lacking IKKalpha. Science (1999) 3.85
The nucleotide sequence of human fibroblast interferon cDNA. Gene (1980) 3.80
The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J (1999) 3.77
Molecular regulation of B lymphocyte response. Annu Rev Immunol (1988) 3.68
Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis. Immunity (1996) 3.66
Structure and expression of human B cell stimulatory factor-2 (BSF-2/IL-6) gene. EMBO J (1987) 3.64
Somatic mutation hotspots correlate with DNA polymerase eta error spectrum. Nat Immunol (2001) 3.60
Phosphorylation at threonine-235 by a ras-dependent mitogen-activated protein kinase cascade is essential for transcription factor NF-IL6. Proc Natl Acad Sci U S A (1993) 3.59